We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » OMQ’s End-of-Year Review Finds Many Issues With Overseas cGMP Practices
OMQ’s End-of-Year Review Finds Many Issues With Overseas cGMP Practices
The FDA repeatedly blasted overseas drugmakers last year for disregarding compliance orders and not living up to their own promises to carry out proper cGMP practices for active pharmaceutical ingredients.
To View This Article:
Login
Subscribe To International Pharmaceutical Regulatory Monitor